99 related articles for article (PubMed ID: 28259948)
1. Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolism.
Lu Y; Zhong H; Tang Q; Huang Z; Jing N; Smith J; Miao R; Li Y; Yuan H
Mol Med Rep; 2017 Apr; 15(4):1593-1600. PubMed ID: 28259948
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5 polymorphism, amlodipine and hypertension.
Zhang YP; Zuo XC; Huang ZJ; Cai JJ; Wen J; Duan DD; Yuan H
J Hum Hypertens; 2014 Mar; 28(3):145-9. PubMed ID: 23863802
[TBL] [Abstract][Full Text] [Related]
3. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects.
Kim KA; Park PW; Park JY
Chirality; 2009 May; 21(5):485-91. PubMed ID: 18752284
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.
Kim KA; Park PW; Lee OJ; Choi SH; Min BH; Shin KH; Chun BG; Shin JG; Park JY
Clin Pharmacol Ther; 2006 Dec; 80(6):646-56. PubMed ID: 17178265
[TBL] [Abstract][Full Text] [Related]
5. Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy.
Cai J; Huang Z; Yang G; Cheng K; Ye Q; Ming Y; Zuo X; Zhou P; Yuan H
Am J Cardiovasc Drugs; 2011 Dec; 11(6):401-9. PubMed ID: 22149319
[TBL] [Abstract][Full Text] [Related]
6. Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
Park KW; Kang J; Park JJ; Yang HM; Lee HY; Kang HJ; Koo BK; Oh BH; Park YB; Kim HS
Heart; 2012 Sep; 98(18):1366-72. PubMed ID: 22735685
[TBL] [Abstract][Full Text] [Related]
7. Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients.
Torio A; Auyanet I; Montes-Ares O; Guerra RM; Fernandez EJ; Perez MA; Ramirez A; Checa MD
Transplant Proc; 2012 Nov; 44(9):2596-8. PubMed ID: 23146466
[TBL] [Abstract][Full Text] [Related]
8. Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors.
Ferraresso M; Turolo S; Ghio L; Tirelli AS; Belingheri M; Villa R; Groppali E; Edefonti A
Clin Exp Hypertens; 2011; 33(6):359-65. PubMed ID: 21851254
[TBL] [Abstract][Full Text] [Related]
9. Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms.
Aquilante CL; Langaee TY; Anderson PL; Zineh I; Fletcher CV
Clin Chim Acta; 2006 Oct; 372(1-2):195-8. PubMed ID: 16701601
[TBL] [Abstract][Full Text] [Related]
10. Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects.
Han JM; Yee J; Chung JE; Lee KE; Park K; Gwak HS
Mol Genet Genomic Med; 2020 May; 8(5):e1201. PubMed ID: 32134573
[TBL] [Abstract][Full Text] [Related]
11. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.
Bhatnagar V; Garcia EP; O'Connor DT; Brophy VH; Alcaraz J; Richard E; Bakris GL; Middleton JP; Norris KC; Wright J; Hiremath L; Contreras G; Appel LJ; Lipkowitz MS;
Am J Nephrol; 2010; 31(2):95-103. PubMed ID: 19907160
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells
Song HY; Xia JS; Chen YG; Chen L
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S646-S653. PubMed ID: 34784831
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells
Song HY; Xia JS; Chen YG; Chen L
Hum Exp Toxicol; 2022; 41():9603271221080236. PubMed ID: 35099304
[TBL] [Abstract][Full Text] [Related]
14. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.
Solas C; Simon N; Drogoul MP; Quaranta S; Frixon-Marin V; Bourgarel-Rey V; Brunet C; Gastaut JA; Durand A; Lacarelle B; Poizot-Martin I
Br J Clin Pharmacol; 2007 Sep; 64(3):353-62. PubMed ID: 17517050
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of CYP3A5 attenuates inducibility and activity of CYP3A4 in HepG2 cells.
Kuang Z; Huang Z; Li Y; Yang G; Liu M; Yuan H
Mol Med Rep; 2015 Apr; 11(4):2868-74. PubMed ID: 25434721
[TBL] [Abstract][Full Text] [Related]
16. Impact of CYP3A5 and MDR-1 gene polymorphisms on the dose and level of tacrolimus among living-donor liver transplanted patients: single center experience.
Fathy M; Kamal M; Mohy A; Nabil A
Biomarkers; 2016; 21(4):335-41. PubMed ID: 26856709
[TBL] [Abstract][Full Text] [Related]
17. Association between cytochrome P450 3A5 polymorphism and the lung function in Saskatchewan grain workers.
Seo T; Pahwa P; McDuffie HH; Yurube K; Egoshi M; Umemoto Y; Ghosh S; Fukushima Y; Nakagawa K
Pharmacogenet Genomics; 2008 Jun; 18(6):487-93. PubMed ID: 18496128
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
Leskelä S; Honrado E; Montero-Conde C; Landa I; Cascón A; Letón R; Talavera P; Cózar JM; Concha A; Robledo M; Rodríguez-Antona C
Endocr Relat Cancer; 2007 Sep; 14(3):645-54. PubMed ID: 17914095
[TBL] [Abstract][Full Text] [Related]
19. [Polymorphisms of CYP3A5 gene in acute leukemia patients and their role in chemotherapy and prognosis].
Shen LJ; Chen FY; Wang T; Wang HR; Zhong JH; Han JY; Ouyang RR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):26-30. PubMed ID: 18315894
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous detection of CYP3A5 and MDR1 polymorphisms based on the SNaPshot assay.
Li L; Li CJ; Zhang YJ; Zheng L; Jiang HX; Si-Tu B
Clin Biochem; 2011 Apr; 44(5-6):418-22. PubMed ID: 21237140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
